Everestmab, a novel long-acting GLP-1/anti GLP-1R nanobody fusion protein, exerts potent anti-diabetic effects.

Autor: Pan, Hongchao1,2 (AUTHOR), Su, Yunnan3 (AUTHOR), Xie, Yini4 (AUTHOR), Wang, Weiyong5 (AUTHOR), Qiu, Wanli5 (AUTHOR), Chen, Wei6 (AUTHOR), Lu, Wenying6 (AUTHOR), Lu, Zhao7 (AUTHOR), Wang, Weiwei6 (AUTHOR), Shang, Anquan2 (AUTHOR)
Zdroj: Artificial Cells, Nanomedicine & Biotechnology. Dec2020, Vol. 48 Issue 1, p854-866. 13p.
Databáze: Academic Search Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje